HB5241 would expand and standardize insurance coverage for breast cancer screening across multiple categories of health coverage in West Virginia, including PEIA, accident and sickness insurance, group insurance, hospital service corporations, medical service corporations, health service corporations, and HMOs. The bill requires coverage for a baseline mammogram for women ages 30 to 39, annual mammograms for women age 40 and older, and earlier or more frequent mammograms for women under 40 when medically necessary because of family history or other risk factors. It also requires coverage for comprehensive ultrasound screening when a mammogram shows dense or heterogeneous breast tissue or when a patient is otherwise considered at increased risk for breast cancer.
In addition to coverage mandates, the bill requires certified radiologists and mammography facilities to notify patients of breast density in their mammography summaries and to include information explaining that dense tissue is not abnormal, describing associated risks, and encouraging patients to consult a primary care physician. The notification provision expressly states that it does not create a standard of care or a private cause of action. The bill applies to policies, contracts, and plans issued, delivered, reissued, extended, or changed on or after January 1, 2026, or when a premium adjustment is made.
The bill’s impact on state law would be to add new insurance mandates and public health disclosure requirements, while also amending existing provisions governing mammography, Pap smears, and HPV testing to clarify that reimbursement may not be denied for medically appropriate cancer screening or diagnostic services. It would affect insurers, health plans, PEIA, mammography facilities, radiologists, and patients seeking breast cancer screening services, likely increasing covered preventive services and potentially increasing utilization and insurer costs.
The general sentiment reflected in the bill text is strongly supportive of expanded breast cancer screening and early detection. Although no committee transcript or vote history is available, the measure’s structure and stated purpose indicate a public health-oriented approach aimed at improving access to screening and informing patients about breast density and related risks. The bill appears to be framed as a preventive care and women’s health measure rather than a controversial coverage restriction or benefit reduction.
Notable points of potential contention include the cost implications for insurers and state health plans, the age at which routine mammography coverage begins, and the requirement to cover supplemental ultrasound screening based on dense breast tissue or elevated risk. Another possible issue is the interaction between state-mandated coverage and existing medical guidelines, since the bill references both physician judgment and national screening standards. However, no recorded opposition or debate is included in the provided materials.
HB5241 would amend West Virginia insurance and public health law by creating new statutory requirements for breast cancer screening coverage and breast density notification. It would require a range of insurers and health plans to cover baseline and annual mammograms, supplemental ultrasound screening in specified circumstances, and related screening services without denial when medically appropriate. It also adds a disclosure requirement for mammography providers and expressly limits liability by stating that the notification law does not create a private cause of action.
The bill appears to have a generally favorable, preventive-care-oriented policy posture, emphasizing early detection, patient education, and expanded access to screening. Because no committee discussion or vote history is provided, there is no documented opposition or support from legislators in the available record. Based on the text alone, the measure is framed as a health coverage expansion intended to benefit patients, particularly women at risk for breast cancer.
The main likely points of contention are fiscal and insurance-policy related: mandated coverage can increase costs for PEIA and private insurers, and supplemental ultrasound coverage may raise utilization and claims expenses. Some may also question whether the bill’s screening ages and dense-breast requirements align with current medical guidelines or create obligations beyond standard preventive care recommendations. The bill attempts to reduce legal exposure by stating that breast density notification does not create a standard of care or private right of action, which may address provider concerns but does not eliminate broader cost or mandate objections.